P 1025

Drug Profile

P 1025

Latest Information Update: 14 Dec 2000

Price : $50

At a glance

  • Originator United Medical and Dental Schools of Guys, Kings and St Thomas Hospitals
  • Class Peptides
  • Mechanism of Action Cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Dental caries

Most Recent Events

  • 14 Dec 2000 Suspended-Preclinical for Dental caries in United Kingdom (Topical)
  • 14 Dec 2000 Actinova has been closed down
  • 26 May 1999 Preclinical development for Dental caries in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top